|Bid||70.12 x 1100|
|Ask||70.16 x 1000|
|Day's Range||69.68 - 70.71|
|52 Week Range||50.77 - 92.18|
|Beta (3Y Monthly)||1.25|
|PE Ratio (TTM)||54.14|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In the weeks leading up to unveiling a $2.8 billion cash-and-stock merger — and especially in the final few days — top executives and directors of Genomic Health Inc. were locked in a fierce back-and-forth with Exact Sciences Corp. that at one point led the pioneering Redwood City-based cancer test maker to reject the deal. In a Securities and Exchange Commission filing late Friday ahead of a Nov. 7 shareholder vote on the deal, Genomic Health (NASDAQ: GHDX) said its board rejected Madison, Wisconsin-based Exact Sciences' (NASDAQ: EXAS) offer before ultimately agreeing to a $72-per-share price. Midway through negotiations, a financial adviser reached out to Genomic Health on behalf of an "unnamed strategic player" based outside the United States that was in the early stages of considering delving into the U.S. health care market via a transaction.
Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.
CFO of Genomic Health Inc (30-Year Financial, Insider Trades) G Bradley Cole (insider trades) sold 43,112 shares of GHDX on 09/10/2019 at an average price of $72.22 a share. Continue reading...
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
President and CEO of Genomic Health Inc (30-Year Financial, Insider Trades) Kimberly J Popovits (insider trades) sold 50,000 shares of GHDX on 08/09/2019 at an average price of $73.76 a share. Continue reading...
The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 1) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Odonate ...
Pfizer announced an all-stock plan Monday to combine its off-patent and generic drugs unit, Upjohn, with generic drug maker Mylan. That sent Mylan stock flying as Pfizer stumbled.
A new ETF is setting its sights on advancing the field of health care technology. ROBO Global Healthcare Technology and Innovation ETF is giving investors another option to capture innovation and growth within the space. Travis Briggs, ROBO Global CEO, discusses with Yahoo Finance's Akiko Fujita on "The Ticker."